Charleston, Daiichi hydrocodone product pact worth up to $650m
This article was originally published in Scrip
Daiichi Sankyo will pay Jupiter, Florida-based Charleston Laboratories $100m up front, a $100m near-term milestone fee and up to $450m for future regulatory and approval milestone under a collaboration to develop and commercialize fixed-dose combination (FDC) hydrocodone products in the US.
You may also be interested in...
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.